Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07289035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.

Study acronym: TMX
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 17, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs. The main questions it aims to answer is: . What medical problems do participants have when taking drug TMX? Participants will: * Take drug TMX every day for 6 months * Visit the clinic once every 28 days for checkups and tests
Trial Details
NCT Number NCT07289035
Lead Sponsor Azienda Ospedaliera Universitaria Integrata Verona
Conditions
(from sponsor)		 Cystic Fibrosis - Complete
Related terms Cystic Fibrosis
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov